Morecroft, I., Pang, L., Baranowska, M., Nilsen, M., Loughlin, L., Dempsie, Y., Millet, C. and MacLean, M. R. (2010) In vivo effects of a combined 5-HT1B receptor/SERT antagonist in experimental pulmonary hypertension. Cardiovascular Research, 85(3), pp. 593-603. (doi: 10.1093/cvr/cvp306) (PMID:19736308)
Full text not currently available from Enlighten.
Publisher's URL: http://dx.doi.org/10.1093/cvr/cvp306
Abstract
<b>Aims</b> A mechanism for co-operation between the serotonin (5-hydroxytryptamine, 5-HT) transporter and 5-HT<sub>1B</sub> receptor in mediating pulmonary artery vasoconstriction and proliferation of pulmonary artery smooth muscle cells has been demonstrated <i>in vitro</i>. Here we determine, for the first time, the <i>in vivo</i> effects of a combined 5-HT<sub>1B</sub> receptor/serotonin transporter antagonist (LY393558) with respect to the development of pulmonary arterial hypertension (PAH) and its <i>in vitro</i> effects in human pulmonary artery smooth muscle cells (hPASMCs) derived from idiopathic PAH (IPAH) patients.<p></p> <b>Methods and results</b> We determined the effects of LY393558 as well as a selective serotonin transporter inhibitor, citalopram, on right ventricular pressure, right ventricular hypertrophy, and pulmonary vascular remodelling in wildtype mice and mice over-expressing serotonin transporter (SERT+ mice) before and after hypoxic exposure. We also compared their effectiveness at reversing PAH in SERT+ mice and hypoxic mice. Further, we examined the proliferative response to serotonin in IPAH hPASMCs. We also clarified the pharmacology of serotonin-induced vasoconstriction and 5-HT<sub>1B</sub> receptor/serotonin transporter interactions in mouse isolated pulmonary artery. Citalopram had a moderate effect at preventing and reversing experimental PAH <i>in vivo</i> whereas LY393558 was more effective. LY393558 was more effective than citalopram at reversing serotonin-induced proliferation in IPAH hPASMCs. There is synergy between 5-HT<sub>1B</sub> receptor and serotonin transporter inhibitors against serotonin-induced vasoconstriction in mouse pulmonary arteries.<p></p> <b>Conclusion</b> 5-HT<sub>1B</sub> receptor and serotonin transporter inhibition are effective at preventing and reversing experimental PAH and serotonin-induced proliferation of PASMCs derived from IPAH patients. Targeting both the serotonin transporter and 5-HT<sub>1B</sub> receptor may be a novel therapeutic approach to PAH.<p></p>
Item Type: | Articles |
---|---|
Keywords: | Pulmonary hypertension, Serotonin, Hypoxia, Serotonin transporter, 5HT1B |
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | MacLean, Professor Margaret and Dempsie, Dr Yvonne and Loughlin, Mrs Lynn and Nilsen, Mrs Margaret and Millet, Dr Caroline and Pang, Miss Louise and Morecroft, Dr Ian |
Authors: | Morecroft, I., Pang, L., Baranowska, M., Nilsen, M., Loughlin, L., Dempsie, Y., Millet, C., and MacLean, M. R. |
Subjects: | Q Science > QH Natural history > QH345 Biochemistry Q Science > QH Natural history > QH301 Biology |
College/School: | College of Medical Veterinary and Life Sciences College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health |
Journal Name: | Cardiovascular Research |
Journal Abbr.: | Cardiovasc Res |
Publisher: | Oxford University Press |
ISSN: | 0008-6363 |
ISSN (Online): | 1755-3245 |
Published Online: | 25 September 2009 |
Related URLs: |
University Staff: Request a correction | Enlighten Editors: Update this record